Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With CancerKevin C. Conlon, Thomas A. Waldmann, Jean M. Decker et al.|Journal of Clinical Oncology|2014Cited by 714
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesThomas A. Waldmann, Stephen P. Creekmore, Enrico Lugli et al.|Blood|2011Cited by 194
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset ExpansionKevin C. Conlon, Thomas A. Waldmann, E. Lake Potter et al.|Clinical Cancer Research|2019Cited by 134
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primatesEnrico Lugli, Mario Roederer, Carolyn K. Goldman et al.|Blood|2010Cited by 123
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.Jeffrey W. Clark, Stephen P. Creekmore, John W. Smith et al.|PubMed|1990Cited by 54